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Primary malignant neoplasms of the liver are some of the most uncommon malignancies in many parts of the world. They include
hepatocellularcarcinomaandstromaltumorssuchashepaticangiosarcoma.Itisalethaltumorwithlifeexpectancyoflessthansix
months. Once discovered, it is often too late for surgical intervention. Like other vascular tumors of the liver and spleen, intraperi-
toneal hemorrhage is a well-documented ﬁnding of angiosarcoma which can be lethal if not diagnosed and treated immediately.
As in our case, intraperitoneal hemorrhage from primary tumor rupture was the only clinical presentation of this neoplasm. Ap-
proximately 15% of patients present with acute hemoperitoneum from either tumor rupture or peritoneal metastasis. Although
several therapeutic options are available, we describe apalliative therapy for hepatic angiosarcoma utilizing transcatheter arterial
chemoembolization (TACE) techniques incorporating the newer embolization agent Embospheres to locally target and treat this
aggressive tumor.
Copyright © 2007 G. W. Stambo and M. J. Guiney. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. REPORT
A 54-year-old male with a past medical history signiﬁcant
for hemachromatosis, coronary bypass graft surgery, with
an ejection fraction of 20%, presented to an outside insti-
tution with clinical and computed tomography ﬁndings of
acute intraperitoneal hemorrhage. At that time, an emergent
mesenteric angiogram was obtained demonstrating a multi-
centricpathologicalvascularmassinvolvingtherighthepatic
lobe (as in Figure 1). Also, no vascular abnormalities were
noted in the left lobe. There was no contrast extravasation
identiﬁed to suggest vascular rupture and, therefore, no en-
dovascular intervention was performed at the outside hos-
pital. Following the angiogram, a CT-guided percutaneous
liver biopsy was performed the next day which was nondi-
agnostic. Two days following the initial intraperitoneal hem-
orrhage, the patient was transferred to our tertiary care in-
stitution where he was admitted to the surgical service. The
patient subsequently underwent an open surgical biopsy the
next morning (see Figure 2). The pathologic sample demon-
stratedadiagnosisofahigh-gradehepaticangiosarcoma.Ul-
trasonography, computed tomography, and magnectic reso-
nance imaging conﬁrmed the ﬁndings of a hepatic neoplasm
involving a signiﬁcant portion of the right hepatic lobe (see
Figure 3). The portal vein was patent and no extrahepatic
disease was present. In light of the patient’s extensive right
hepatic involvementandmultiple comorbidities, thesurgical
option was regarded no feasible by the attending hepatic sur-
geon. The patient was referred to our service for endovascu-
lar management. Following consultation with the family dis-
cussing the palliative nature of the chemoembolization pro-
cedure,thepatientwasbroughttotheinterventionalsuitefor
transarterial chemoembolization (TACE) ﬁve days following
initial presentation.
A 5 French cobra catheter (Terumo/Boston Scientiﬁc,
Natick, Mass, USA) was advanced into the right hepatic
artery and a selective hepatic arteriogram was obtained with
particular attention to pertinent hepatic arterial anatomy.
Ad i ﬀusely vascular enhancing mass consistent with the di-
agnosis of hepatic angiosarcoma was conﬁrmed along with
other satellite masses in the superior surface of the right
lobe. Again, no arterial contrast extravasation was noted on2 Sarcoma
Figure 1: Selective right hepatic arteriogram demonstrating an ex-
tensive vascular mass right lobe liver. No evidence of contrast ex-
travasations to suggest acute hemorrhage at this time.
this exam to suggest intraperitoneal hemorrhage. The por-
tal vein was patent. TACE was performed with a combina-
tion of ethiodol (lipidol) (Savage Laboratories, Melville, NY,
USA), Embospheres 500–700µm (Biosphere Medical, Rock-
land, Mass, USA) and mixture of Doxorubicin and Mito-
mycin C (Bedford Laboratories, Bedford, Ohio, USA). Dur-
ing embolization, stasis of ﬂow was identiﬁed within the tu-
mor vascularity consistent with occlusion of the neovascu-
lar feeding vessels to the mass. Successful embolization was
noted ﬂuoroscopically with diﬀuse uptake of the ethiodol
solution within the tumor resulting in a “snow storm” up-
take pattern (see Figure 4). There were no postprocedure
complications. The patient was discharged to home in two
days without developing postembolization syndrome and
was asymptomatic for three months. He was aware that if
new lesions or residual enhancing tumor were identiﬁed on
the followup studies that repeating TACE procedure would
be recommended at that time. No further TACE procedures
were performed during this time interval and his followup
CT imaging at three months demonstrated no residual or
newenhancingtumor,diﬀusenecrosisoftheprevioustumor
bed, and ethiodol scattered throughout the tumor masses
(Figure 5). Unfortunately, the patient succumbed to his un-
derlying comorbidities and died suddenly of an acute my-
ocardial infarction four months after his procedure.
2. DISCUSSION
Hepatic malignancies include hepatocellular carcinoma, gas-
trointestinal and nongastrointestinal metastases, and pri-
mary or metastatic sarcomas [1]. A primary sarcoma of the
liveristhehepaticangiosarcoma.Angiosarcomasaccountfor
only 2% of all primary hepatic malignancies [1–6]. They
have a high malignant potential resulting in a poor prog-
nosis with death in less than one year. They are surgically
unresectable at the time of diagnosis due to multiple tu-
mors, high pathologic grade, and rapid-growing tumor bur-
den [7]. This tumor occurs exclusively in late adulthood to
Figure 2:Intraoperativecolorphotographdemonstratingthelobu-
lated blood ﬁlled cystic mass consistent with hepatic angiosarcoma.
those who have been exposed to environmental toxins such
as polyvinylcholoride monomers, thorium dioxide (Thoro-
trast), and arsenic insecticides [1, 2, 4] .T h e r ei sar a r ec o r r e -
lation between hemachromatosis and hepatic angiosarcoma
[1, 3, 7, 8]. Our patient had hemachromatosis without other
environmental factors for hepatic angiosarcoma. Further-
more, 15% of angiosarcomas present with intraperitonealG. W. Stambo and M. J. Guiney 3
Figure 3: CT scan abdomen with contrast demonstrated highly
vascular tumor with heterogeneous uptake pattern consistent with
hepatic angiosarcoma.
Figure 4: Right hepatic angiogram following chemoembolization
of the hepatic angiosarcoma demonstrating the “snow storm” ap-
pearance consistent with diﬀuse uptake and entrapment of the
ethiodol within the tumor.
hemorrhage which can be lethal in some patients [2]. Our
patient presented with hemoperitoneum from tumor rup-
ture. Furthermore, metastatic liver gastrointestinal stromal
tumors are rare but are more common than primary hepatic
angiosarcoma. These liver metastases present with bleeding
complications (30–40%); and selective arterial embolization
has been used for palliation of the gastrointestinal hemor-
rhage[9].WedescribetheﬁrstcaseintheEnglishlanguageof
TACEinvolvinganunresectablehepaticangiosarcomautiliz-
ing Embospheres into the neovascular branches of the neo-
plasm [10, 11]. Due to the large tumor burden, multiple
TACE procedures were expected for this patient. However,
Figure 5: Three month followup CT scan abdomen with contrast
demonstratingnoenhancingtumorremainingfollowingTACE.Ex-
tensive necrosis and deposition of ethiodol trapped within tumor.
the response following one TACE with Embospheres was ex-
cellent in this short interval. Tumor necrosis and ethiodol
material were visualized on followup CT scan images con-
sistent with a good postembolization result. The advantage
of TACE is its ability to selectively deliver chemotherapeu-
tic agent and embolic material to the tumor while sparring
surrounding liver tissue without concurrent systemic toxi-
city [12]. We feel that the addition of Embospheres to our
TACE regimen has improved tumor killing and subsequent
necrosis due to its unique malleable conforming properties
notavailableinotheremoblizationdevicesallowingformore
homogeneous neovascular arterial occlusion. Embospheres
are available in various sizes providing further options for
other vascular territories such as uterine artery ﬁbroid em-
bolization.
Recently, transarterial placement of yttrium-90 glass mi-
crospheres (90Y-uS; TheraSphere, MDS Nordion, Ottawa,
ON, Canada), SIR-sphere (SIRTex Medical Inc., Lake Forest,
Ill, USA), and LC beads (Angiodynamics, Queensbury, NY,
USA) for the treatment of unresectable hepatocellular carci-
noma and colorectal metastasis respectfully are available in
the United States [13]. Also, depending on size of the tumor,
percutaneous therapy utilizing radio frequency thermal ab-
lation is readily available for various organs [14]. These op-
tionsmayplayaroleinthepalliativemanagementofpatients
with unresectable angiosarcoma depending on size, location,
and tumor burden within the liver. In patients with accept-
able liver function, the palliative nature of TACE with its
good risk to beneﬁt ratio makes this procedure a useful op-
tion with other types of malignant liver neoplasms including
gastrointestinal and neuroendocrine metastasis. The abso-
lutecontraindicationstoTACEincludeextensiveliverdisease
and intractable infection [12]. Relative contraindications in-
clude portal vein thrombosis, uncorrectable coagulopathy,
and poor renal function [12]. Those patients with tumor
thrombus in the portal vein are considered contraindicated
because of increased risk of liver failure due to hepatic is-
chemia [15]. Therefore, when selecting patients for TACE,4 Sarcoma
those patients with advanced liver disease may neutralize the
survival beneﬁt of the intervention. Endovascular specialists
should be aware that TACE is a reliable alternative for pa-
tients with unresectable hepatic neoplasms such as angiosar-
coma.
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